Clinical trial
Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With…
NCT00006145 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00006145 |
|---|---|
| Title | Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV |
| Official title | A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Infections, HIV Infections |
| Intervention type | Drug |
| Interventions | Valganciclovir |
| Enrollment | 350 |
| Start date | Aug 1, 2000 |
| Completion | Feb 1, 2006 |
| First posted | Aug 31, 2001 |
| Last update posted | Nov 1, 2021 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: